{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Yu H"],"funding":["Medical Scientific Research Foundation of Guangdong Province","National Natural Science Funds of China","Natural Science Foundation of Guangdong Province"],"pagination":["e003431"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8576478"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["9(11)"],"pubmed_abstract":["Anti-PD-1)/programmed cell death-ligand 1 (PD-L1) antibody plus platinum-based chemotherapy (PBC) has replaced PBC as first-line treatment for patients with non-squamous (sq) non-small cell lung cancer (NSCLC) lacking targetable driver mutations. However, few studies have directly compared immune checkpoint inhibitor (ICI) plus chemotherapy with bevacizumab plus chemotherapy (beva +chemo) in this setting. Herein, we conducted an indirect comparison for anti-PD-1/PD-L1 antibody plus chemotherapy (ICI +chemo) versus beva +chemo in non-sq NSCLC using the frequentist methods. The main outcomes analyzed include progression-free survival (PFS), overall survival (OS), and objective response rate (ORR). Data were subtracted from randomized trials comparing ICI +chemo or beva +chemo against PBC. Fo"],"journal":["Journal for immunotherapy of cancer"],"pubmed_title":["PD-1/PD-L1 inhibitor plus chemotherapy versus bevacizumab plus chemotherapy in first-line treatment for non-squamous non-small-cell lung cancer."],"pmcid":["PMC8576478"],"funding_grant_id":["8217102281","2019A1515011596, 2019A1515011090","81972898","C2019110","81903176"],"pubmed_authors":["Chen P","Fu S","Xia L","Zhang X","He L","Chen C","Zhou Y","Zhang B","Yu H","Hong S"],"additional_accession":[]},"is_claimable":false,"name":"PD-1/PD-L1 inhibitor plus chemotherapy versus bevacizumab plus chemotherapy in first-line treatment for non-squamous non-small-cell lung cancer.","description":"Anti-PD-1)/programmed cell death-ligand 1 (PD-L1) antibody plus platinum-based chemotherapy (PBC) has replaced PBC as first-line treatment for patients with non-squamous (sq) non-small cell lung cancer (NSCLC) lacking targetable driver mutations. However, few studies have directly compared immune checkpoint inhibitor (ICI) plus chemotherapy with bevacizumab plus chemotherapy (beva +chemo) in this setting. Herein, we conducted an indirect comparison for anti-PD-1/PD-L1 antibody plus chemotherapy (ICI +chemo) versus beva +chemo in non-sq NSCLC using the frequentist methods. The main outcomes analyzed include progression-free survival (PFS), overall survival (OS), and objective response rate (ORR). Data were subtracted from randomized trials comparing ICI +chemo or beva +chemo against PBC. Fo","dates":{"release":"2021-01-01T00:00:00Z","publication":"2021 Nov","modification":"2026-07-16T18:28:26.027Z","creation":"2026-07-09T11:14:42.823Z"},"accession":"S-EPMC8576478","cross_references":{"pubmed":["34750245"],"doi":["10.1136/jitc-2021-003431"]}}